PMID- 36030394
OWN - NLM
STAT- MEDLINE
DCOM- 20221114
LR  - 20221114
IS  - 1600-0609 (Electronic)
IS  - 0902-4441 (Linking)
VI  - 109
IP  - 6
DP  - 2022 Dec
TI  - The safety of Bruton's tyrosine kinase inhibitors in B-cell malignancies: A 
      systematic review.
PG  - 696-710
LID - 10.1111/ejh.13854 [doi]
AB  - B-cell malignancies, most notably lymphomas, make up most of the non-Hodgkin 
      lymphomas in the United States. There are limited randomized data comparing 
      first- and second-generation Bruton tyrosine kinase (BTK) inhibitors. Our aim was 
      to compare the safety profiles of first versus second-generation BTK inhibitors. 
      A systematic search was performed from database inception to January 13, 2020. 
      Studies with BTK inhibitor monotherapy for the treatment of B-cell malignancies 
      in the adult population (>18 years old) were utilized and the adverse events 
      (AEs) were extracted. Fifty-five studies that met the inclusion criteria were 
      included in the systematic review with 41 studies with first generation and 14 
      studies with second generation. The review included both clinical trials and 
      retrospective studies with average time of follow-up of 2 years for the 
      first-generation group and 18 months for the second-generation group. We found 
      that the incidence of cardiovascular AEs was significantly higher in the 
      first-generation group (20.8%) as compared to the second-generation group (6.3%). 
      However, there was a higher incidence of hematologic/oncologic and 
      gastrointestinal side effects in the second-generation group compared to the 
      first (62.3% compared to 39.2% and 36.9% compared to 28.9%). The number of Grade 
      5 cardiovascular events (death) was same in the first-generation group compared 
      to the second generation. Further research is needed to develop highly selective 
      BTK inhibitors to avoid unwanted AEs by minimizing off-targets.
CI  - (c) 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Arustamyan, Michael
AU  - Arustamyan M
AD  - Section of Clinical Cardiology, Department of Cardiovascular Medicine, Heart, 
      Vascular and Thoracic Institute, Cleveland, Ohio, USA.
AD  - Cleveland Clinic, Section of Leukemia/Lymphoma, Department of Hematology and 
      Medical Oncology, Cleveland, Ohio, USA.
FAU - Kibrik, Pavel
AU  - Kibrik P
AD  - Section of Clinical Cardiology, Department of Cardiovascular Medicine, Heart, 
      Vascular and Thoracic Institute, Cleveland, Ohio, USA.
AD  - Cleveland Clinic, Section of Leukemia/Lymphoma, Department of Hematology and 
      Medical Oncology, Cleveland, Ohio, USA.
FAU - Hatipoglu, Dilara
AU  - Hatipoglu D
AD  - Section of Clinical Cardiology, Department of Cardiovascular Medicine, Heart, 
      Vascular and Thoracic Institute, Cleveland, Ohio, USA.
AD  - Cleveland Clinic, Section of Leukemia/Lymphoma, Department of Hematology and 
      Medical Oncology, Cleveland, Ohio, USA.
FAU - Bungo, Brandon
AU  - Bungo B
AD  - Section of Clinical Cardiology, Department of Cardiovascular Medicine, Heart, 
      Vascular and Thoracic Institute, Cleveland, Ohio, USA.
AD  - Cleveland Clinic, Section of Leukemia/Lymphoma, Department of Hematology and 
      Medical Oncology, Cleveland, Ohio, USA.
AD  - Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic 
      Foundation, Cleveland, Ohio, USA.
FAU - Mentias, Amgad
AU  - Mentias A
AD  - Section of Clinical Cardiology, Department of Cardiovascular Medicine, Heart, 
      Vascular and Thoracic Institute, Cleveland, Ohio, USA.
AD  - Cleveland Clinic, Section of Leukemia/Lymphoma, Department of Hematology and 
      Medical Oncology, Cleveland, Ohio, USA.
FAU - Hill, Brian T
AU  - Hill BT
AD  - Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic 
      Foundation, Cleveland, Ohio, USA.
FAU - Moudgil, Rohit
AU  - Moudgil R
AUID- ORCID: 0000-0001-8258-0675
AD  - Section of Clinical Cardiology, Department of Cardiovascular Medicine, Heart, 
      Vascular and Thoracic Institute, Cleveland, Ohio, USA.
AD  - Cleveland Clinic, Section of Leukemia/Lymphoma, Department of Hematology and 
      Medical Oncology, Cleveland, Ohio, USA.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20220929
PL  - England
TA  - Eur J Haematol
JT  - European journal of haematology
JID - 8703985
RN  - 0 (Protein Kinase Inhibitors)
SB  - IM
MH  - Humans
MH  - Adolescent
MH  - *Protein Kinase Inhibitors/adverse effects
MH  - Retrospective Studies
MH  - B-Lymphocytes
MH  - *Neoplasms/drug therapy
OTO - NOTNLM
OT  - B-cell malignancies
OT  - bruton tyrosine kinase inhibitors
OT  - systematic review
EDAT- 2022/08/29 06:00
MHDA- 2022/11/15 06:00
CRDT- 2022/08/28 04:12
PHST- 2022/08/17 00:00 [revised]
PHST- 2022/07/12 00:00 [received]
PHST- 2022/08/19 00:00 [accepted]
PHST- 2022/08/29 06:00 [pubmed]
PHST- 2022/11/15 06:00 [medline]
PHST- 2022/08/28 04:12 [entrez]
AID - 10.1111/ejh.13854 [doi]
PST - ppublish
SO  - Eur J Haematol. 2022 Dec;109(6):696-710. doi: 10.1111/ejh.13854. Epub 2022 Sep 
      29.